Re-recognition of treatments in patients of non-small cell lung cancer harboring EGFR-TKI resistance
HE Yuan
YOU Changxuan
Abstract：Globally, lung cancer is the leading cause of cancer?related death with high morbidity, mortality and poor prognosis. The epidermal growth factor receptor?tyrosine kinase inhibitor( EGFR?TKI) , a means of molecularly targeted therapy, offers a novel ap?proach for the treatment of patients with NSCLC harboring EGFR mutation effectively. However, the problem of EGFR?TKI resistance ex?ists inevitably. A number of promising strategies based on different mechanisms have now been evaluated in phaseⅠ/Ⅱtrials. These in?clude EGFR?TKI discontinuation, EGFR?TKI continuing, EGFR?TKI+local treatment, EGFR+other molecularly targeted drugs, EGFR?TKI+chemotherapy, EGFR?TKI rechallenge, chemotherapy, chemotherapy+other molecularly targeted drugs and EGFR?TKI+immunother?apy. The purpose of this paper will draw a summary on the progress of treatments in patients with NSCLC harboring EGFR?TKI resistance.
Keywords：Non-small cell lung cancer(NSCLC)EGFR-TKIDrug-resistanceProgress of treatment
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 848-851 )